1-(3-氟苯基)哌嗪 | 3801-89-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(3-氟苯基)哌嗪
• 中文别名: 1-（3-氟苯基）哌嗪
• 英文名称: 1-(3-fluorophenyl)piperazine
• 英文别名: N-2-fluoro-benzyl-piperazine
• CAS: 3801-89-6
• 化学式: C₁₀H₁₃FN₂
• 分子量: 180.225
• InChiKey: KIFCSMQTGWVMOD-UHFFFAOYSA-N

物化性质

• 沸点：
  88-91°C 0,2mm
• 密度：
  1.112±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 安全说明：
  S26,S36/37/39
• 危险品运输编号：
  UN3334
• 海关编码：
  2933599090
• 危险品标志：
  Xi
• 危险类别码：
  R20/21/22

反应信息

• 作为反应物：
  描述：

  1-(3-氟苯基)哌嗪 在 palladium on activated charcoal 氢气 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、344.75 kPa 条件下， 反应 20.0h， 生成 2-Amino-1-[4-(3-fluorophenyl)piperazin-1-yl]ethanone
  参考文献：
  名称：

  From Tyrosine to Glycine:  Synthesis and Biological Activity of Potent Antagonists of the Purinergic P2X₇ Receptor

  摘要：

  The characterization of the native and recombinant P2X(7) receptor continues to be hindered by the lack of specific and subtype-selective antagonists with a "druglike" profile. However, a tyrosine derivative named KN-62 exhibits selective P2X(7) receptor-blocking properties. As a molecular simplification of KN-62, the present study was designed to evaluate the functional antagonistic properties of a novel series of glycine derivatives characterized by the presence of different phenyl-substituted piperazine moieties. Antagonistic activity of these glycine derivatives was tested on HEK293 cells transfected with the human P2X(7) receptor. The most potent P2X(7) receptor antagonist identified in this study (compound 4g) contains an o-fluorine substituent on the phenylpiperazine moiety and had an IC50 of 12.1 nM. The biological responses investigated were ATP-dependent Ca2+ influx across the plasma membrane and ethidium bromide uptake.

  DOI：

  10.1021/jm070443e
• 作为产物：
  描述：

  3-[2-(3-Fluoroanilino)ethyl]-1,3-oxazolidin-2-one 在 氢溴酸 作用下， 生成 1-(3-氟苯基)哌嗪
  参考文献：
  名称：

  使用2-恶唑烷酮作为潜在的氮丙啶等效物。三，N-取代的哌嗪的制备

  摘要：

  由各种取代的2-恶唑烷酮衍生物3制备了许多N-芳基和N-烷基取代的哌嗪1。该方法包括在冰醋酸中用HBr处理3，然后在醇溶剂中加热所得的开环盐5。通过结晶分离出哌嗪1a-1q，产率为23-91％。

  DOI：

  10.1016/0040-4039(94)85306-1

文献信息

• [EN] NOVEL AGENTS TARGETING CYP51<br/>[FR] NOUVEAUX AGENTS CIBLANT CYP51
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2015048306A1

  公开（公告）日：2015-04-02

  The invention provides inhibitors of a sterol C14-demethylase, a new series of 4- aminopyridyl-based lead inhibitors targeting Trypanosoma cruzi CYP51 (TcCYP51) developed using structure-based drug design as well as structure -property relationship (SPR) analyses. The screening hit starting point, LP 10 (KD < 42 nM; EC50 of 0.65 μΜ), has been optimized to give the potential leads that have low nanomolar binding affinity to TcCYP51 and significant activity against T. cruzi amastigotes cultured in human myoblasts. Many of the optimized compounds have improved microsome stability, and most are selective against the T. cruzi CYP51 relative to human CYPs 1A2, 2D6 and 3A4 (<50% inhibition at 1 μΜ). A rationale for the improvement of microsome stability and selectivity of inhibitors against human metabolic CYP enzymes is presented. In addition, the binding mode of several compounds of the invention with the T. brucei CYP51 (TbCYP51) ortholog has been characterized by x-ray structure analysis. Orally active compounds and their cyclodextrin complexes have been shown to be effective against Chagas-infected mice.

  该发明提供了一种甾醇C14-去甲基酶的抑制剂，这是一种新系列基于4-氨基吡啶的首选抑制剂，通过基于结构的药物设计以及结构-性质关系（SPR）分析来瞄准Trypanosoma cruzi CYP51（TcCYP51）而开发的。筛选起始点LP 10（KD < 42 nM；EC50为0.65 μΜ）已经经过优化，产生了具有低纳摩尔级别结合亲和力和对在人类肌细胞培养的T. cruzi游离体的显著活性的潜在首选抑制剂。许多经过优化的化合物具有改善的微粒体稳定性，大多数相对于人类CYPs 1A2、2D6和3A4对T. cruzi CYP51具有选择性（在1 μΜ下<50%的抑制）。提出了改善微粒体稳定性和抑制剂对人类代谢CYP酶的选择性的理由。此外，通过X射线结构分析表征了该发明的几种化合物与T. brucei CYP51（TbCYP51）同源物的结合方式。口服活性化合物及其环糊精复合物已被证明对克氏病感染的小鼠有效。
• Development of Thieno[3`,2`:5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide Derivatives as the Estrogen Receptor Ligands: Synthesis, Characterization and Biological Activity
  作者：Xin Wang、Rui Sun、Yushu Huang、Yisi Yan、Miaomiao Gao、Dan-Ni Wang、Diwa Koirala、Da-Wei Li、Chun Hu

  DOI：10.2174/1573406410666140428145753

  日期：2014.10.23

  Estrogen receptors (ERs) are members of a superfamily of ligand-modulated nuclear receptors, which have been associated with an increased risk of cardiovascular diseases and breast cancer. Based on molecular docking studies, 1,4-dihydrothieno[3’,2’:5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide derivatives as estrogen receptor inhibitors with a new scaffold , have been synthesized and tested for the antitumor activity on the ER expressing (ER dependent) human MCF-7 breast cancer cell line. According to the biological activity evaluation, compound 6a demonstrated the most potent antiproliferative activity (relative inhibitory rate: 100%). Several of these compounds exhibited moderate antitumor activity and worthy of further modification to obtain more potent anticancer candidate drugs.

  雌激素受体（ERs）属于配体调节核受体超级家族，与心血管疾病和乳腺癌风险增加有关。基于分子对接研究，我们合成并测试了具有新型骨架的1,4-二氢噻吩并[3’,2’:5,6]噻吔并[4,3-c]吡唑-3-羧酰胺衍生物作为雌激素受体抑制剂，对表达ER的人类MCF-7乳腺癌细胞株的抗肿瘤活性。生物活性评估显示，化合物6a表现出最强的抗增殖活性（相对抑制率：100%）。多个化合物显示出中等抗肿瘤活性，值得进一步改造以获得更强的候选抗癌药物。
• [EN] QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS<br/>[FR] DERIVES D'ACIDE CARBOXYLIQUE DE QUINOLONE POUR LE TRAITEMENT DES TROUBLES HYPERPROLIFERATIFS
  申请人：BAYER PHARMACEUTICALS CORP

  公开号：WO2005097752A1

  公开（公告）日：2005-10-20

  Quinolone carboxylic acid derivatives of formula (I) wherein Ar is an optionally substituted phenyl, pyridyl, or pyrimidinyl group and the substituent groups R1, R4, R10, R11, R19, and R20 are as defined in the specification, pharmaceutical compositions containing them, and methods of using them in treatment of hyperproliferative diseases such as cancer are disclosed and claimed.

  公开和声明了式(I)的喹诺酮羧酸衍生物，其中Ar是可选择地取代的苯基、吡啶基或嘧啶基，取代基R1、R4、R10、R11、R19和R20如规范中定义，包含它们的药物组合物，以及在治疗癌症等高增殖性疾病中使用它们的方法。
• Binding Kinetics of ZM241385 Derivatives at the Human Adenosine A_2AReceptor
  作者：Dong Guo、Lizi Xia、Jacobus P. D. van Veldhoven、Marc Hazeu、Tamara Mocking、Johannes Brussee、Adriaan P. IJzerman、Laura H. Heitman

  DOI：10.1002/cmdc.201300474

  日期：2014.4

  compound’s binding kinetics have been largely ignored, the importance of which is now being increasingly recognized. In the present study, we performed an extensive structure–kinetics relationship (SKR) study in addition to a traditional SAR analysis at the adenosine A2A receptor (A2AR). The ensemble of 24 A2AR compounds, all triazolotriazine derivatives resembling the prototypic antagonist ZM241385 (4‐(

  经典药物的设计和开发主要依赖于亲和力或效价驱动的结构-活性关系（SAR）。迄今为止，给定化合物的结合动力学已被很大程度上忽略，其重要性现在越来越被人们所认识。在本研究中，除了对腺苷A 2A受体（A 2A R）进行传统的SAR分析外，我们还进行了广泛的结构动力学关系（SKR）研究。由24 A 2A R化合物组成的化合物，所有三唑三嗪衍生物均类似于原型拮抗剂ZM241385（4-（2-（（7-氨基-2-（呋喃-2-基）-[1,2,4]三唑[1， 5一] [1,3,5] triazin-5-基）氨基）乙基）苯酚）在亲和力上仅显示微小差异，尽管它们与受体的解离速率差异很大。我们相信，像我们对A 2A R所做的那样，SKR和SAR分析的这种结合对于G蛋白偶联受体的超家族将具有普遍的重要性，因为它可以作为调整配体之间相互作用的新策略和受体。
• Synthesis of N-Substituted Piperazinyl Carbamoyl and Acetyl Derivatives of Tetrahydropapaverine: Potent Antispasmodic Agents.
  作者：Jaskiran Kaur、Narendra Nath Ghosh、Anita Talwar、Ramesh Chandra

  DOI：10.1248/cpb.50.1223

  日期：——

  effect of electron releasing and electron withdrawing substituents upon the antispasmodic activity of the molecules. Effect of varying electron densities on the antispasmodic activity, by altering the position of these groups on the benzene ring has also been monitored. Pharmacological methods involve the in vitro antispasmodic activity studies on a freshly removed guinea pig ileum using a force displacement

  已经进行了四氢罂粟碱的一系列N-取代的哌嗪基氨基甲酰基7-15和哌嗪基乙酰基18-26衍生物的合成和结构活性关系（SAR）。氨基甲酰基四氢罂粟碱类似物的一般合成方法以N-取代的哌嗪和氨基甲酰基咪唑四氢罂粟碱为起始原料。也已经探索了合成这些化合物的另一种途径，包括形成氨基甲酰基咪唑哌嗪。酰化四氢罂粟碱，然后用各种哌嗪基部分取代，得到乙酰基四氢罂粟碱衍生物。已经使用了各种取代的哌嗪来监测电子释放和吸电子取代基对分子的解痉活性的影响。还已经监测了通过改变这些基团在苯环上的位置，改变电子密度对解痉活性的影响。药理方法包括使用连接到生理描记器的力位移传感器放大器对刚摘下的豚鼠回肠进行体外解痉活性研究。在本研究中合成的类似物中，已经获得了有希望的化合物7，与罂粟碱相比，它是一种强效的肌肉松弛剂。